Phase 4 Migraine Trial, Recruiting NCT06401642 Sponsor: Mayo Clinic Condition: Migraine
Back to Migraine

Phase 4 Migraine Trial, Recruiting

NCT06401642
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with migraine (with or without aura) according to standard medical guidelines
  • You are at least 18 years old
  • You experience between 2 and 8 migraine attacks per month
  • You are already taking one of the following migraine prevention medications at a steady dose: atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, or rimegepant — and have been on that stable dose for at least 2 months (or have had at least 2 injections if you receive a once-every-3-months injection)
  • You may have either episodic migraine (occasional attacks) or chronic migraine (more frequent attacks)
  • You are allowed to be taking other migraine prevention treatments alongside the ones listed above, as long as those have also been at a stable dose for at least 2 months

Additional requirements if you would be starting rimegepant as your prevention medication during this trial:

  • You have had 4 or more migraine days per month on average over the past 2 months (based on your own reported experience)

Who may not be able to join:

  • You have another type of primary headache disorder besides migraine (note: tension-type headaches are still allowed)
  • You have previously had an allergic or hypersensitivity reaction to zavegepant or any of its ingredients
  • You have previously had an allergic or hypersensitivity reaction to rimegepant or any of its ingredients (applies only to those being considered for rimegepant as part of the trial)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Registry
ClinicalTrials.gov
Start date
22 March 2024
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Headache relief in 2 hours; Headache relief in 4 hours; Functional disability level in 2 hours; Functional disability level in 4 hours

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov